Articles similar to: urinary incontinence drugs

drugs for overactive bladder (OAB)

Versameb AG Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence

Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application of VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), for the treatment of stress urinary incontinence (SUI).  Following this clearance, Versameb plans to launch a Phase 2a open label, first-in-human dose ascending study in the first half of 2024. The study will evaluate the safety, tolerability, and efficacy of VMB-100 in female subjects with stress urinary incontinence, a highly common condition resulting in involuntary leakage of urine due to a weakened urinary sphincter muscle. Read more.

Source: Pharmaweb.com, November 17, 2023

drugs for overactive bladder (OAB)

Black Patients Less Likely to Fill Prescriptions For Newer, Safer Urinary Incontinence Drugs

Millions of adults take medications to help relieve symptoms of overactive bladder and reduce episodes of urinary incontinence.  But research linking some of those medications called anticholinergic drugs, such as oxybutynin, to memory loss drove recommendations to treat urinary incontinence with beta-3 agonists, drugs that offer the same benefit but without the risk of cognitive decline.  A new study in JAMA Network Open led by Northwestern Medicine and Duke University School of Medicine shows Black patients are less likely to fill prescriptions for newer, safer urinary incontinence drugs compared to white patients, potentially raising their risk for dementia.  Read more.

Source: Duke University School of Medicine, June 12, 2023